First gene-editing therapy could win FDA approval to treat sickle cell disease - crippling condition that leaves sufferers in life-altering pain

A US FDA advisory committee announced it would consider approving the gene-editing drug Casgevy to treat sickle cell disease, which affects 100,000 Americans. It has been approved in the UK.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news